Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study

Diabetes Care

Volumn 41, Issue 12, 2018, Pages 2552-2559

  Dandona, Paresh ^a   Mathieu, Chantal ^b   Phillip, Moshe ^c,d   Hansen, Lars ^e   Tschöpe, Diethelm ^f,g   Thorén, Fredrik ^h   Xu, John ⁱ   Langkilde, Anna Maria ^h  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e BRISTOL MYERS SQUIBB   (United States)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BODY WEIGHT LOSS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DEHYDRATION; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRACTURE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HEPATOBILIARY DISEASE; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM;

ADULT; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PLACEBOS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 85056803873     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-1087     Document Type: Article

References (36)

1. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978
2. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 2010;33:17-22
3. Eliaschewitz FG, Barreto T. Concepts and clinical use of ultra-long basal insulin. Diabetol Metab Syndr 2016;8:2
4. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551-559
5. Sun YN, Zhou Y, Chen X, Che WS, Leung SW. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open 2014;4:e004619
6. Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2014;30:204-221
7. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol 2015;14:142
8. Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 2016;4:211-220
9. Dandona P, Mathieu C, Phillip M, et al.; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:864-876
10. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a work-group of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36: 1384-1395
11. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-1343 ¨
12. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducingweightandbodyfatmassover2yearsin patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014;16:159-169
13. Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 2016;39:2036-2041
14. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-419
15. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377:2337-2348
16. Perkins BA, Cherney DZI, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-1483
17. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015;38:2258-2265
18. Mathieu C, Dandona P, Gillard P, et al.; DEPICT-2 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care 2018;41:1938-1946
19. Orchard TJ, Nathan DM, Zinman B, et al.; Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45-53
20. Lind M, Svensson A, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014;371:1972-1982
21. Nathan DM; DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications study at 30 years: overview. Diabetes Care 2014;37:9-16
22. Bogers RP, Bemelmans WJ, Hoogenveen RT, et al.; BMI-CHD Collaboration Investigators. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007;167: 1720-1728
23. Jonsson S, Hedblad B, Engström G, Nilsson P, Berglund G, Janzon L. Influence of obesity on cardiovascular risk. Twenty-three-year followup of 22,025 men from an urban Swedish population. Int J Obes Relat Metab Disord 2002;26:1046-1053
24. Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med 2010;27:398-404
25. Evans JM, Newton RW, Ruta DA, MacDonald TM, Morris AD. Socio-economic status, obesity and prevalence of type 1 and type 2 diabetes mellitus. Diabet Med 2000;17:478-480
26. Ridderstråle M, Gudbjörnsdottir S, Eliasson B, Nilsson PM, Cederholm J; Steering Committee of the Swedish National Diabetes Register (NDR). Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 2006;259: 314-322
27. Purnell JQ, Zinman B, Brunzell JD; DCCT/EDIC Research Group. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation 2013;127:180-187
28. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA 1998;280: 140-146
29. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-1031
30. Wing RR, Lang W, Wadden TA, et al.; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34: 1481-1486
31. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997;21(Suppl. 1):S5-S9
32. McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. Diabetes 2010;59:2333-2339
33. Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord 2012; 11:17
34. Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411-3419
35. Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortalitydUnited States, 2000-2014. MMWR Morb Mortal Wkly Rep 2018;67:362-365
36. Patel NS, Van Name MA, Cengiz E, et al. Altered patterns of early metabolic decompen-sation in type 1 diabetes during treatment with a SGLT2 inhibitor: an Insulin Pump Suspension Study. Diabetes Technol Ther 2017;19:618-622